Earnings ·
Tenax Therapeutics reported second quarter 2026 financial results on July 31, 2026
TENXTenax Therapeutics, Inc.
Tenax Therapeutics reported second quarter 2026 financial results on July 31, 2026. The company ended the period with $118.0 million in cash and cash equivalents, extending its operational runway through the second quarter of 2028 following $13.4 million in proceeds from warrant exercises. Research and development expenses rose to $12.9 million from $6.1 million year-over-year due to costs for Phase 3 LEVEL and LEVEL-2 trials, while net loss widened to $17.8 million from $10.9 million. The company expects to report topline data from the Phase 3 LEVEL clinical trial in August 2026 and plans to present these results at the European Society of Cardiology Congress. Tenax Therapeutics is a development-stage pharmaceutical company focused on novel cardiopulmonary therapies for pulmonary hypertension associated with heart failure.